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Marrow stromal cells (MSCs, also termed mesenchymal stem cells) have been proposed as a promising cellular therapy for tissue
injury including radiation-induced marrow failure, but evidence for a direct eﬀect is lacking. To assess the eﬀects of MSCs on
survival after lethal irradiation, we infused syngeneic MSCs (either as immortalized MSCs clones or primary MSCs) intravenously
into wild-type C57/Bl6 mice within 24 hours of lethal total body irradiation (TBI). Mice receiving either of the MSC preparations
had signiﬁcantly improved survival when compared to controls. In vivo imaging, immune histochemistry, and RT-PCR employed
to detect MSCs indicated that the infused MSCs were predominantly localized to the lungs and rapidly cleared following infusion.
Our results suggest that a single infusion of MSCs can improve survival after otherwise lethal TBI but the eﬀect is not due to a
direct interaction with, or contribution to, the damaged marrow by MSCs.
1.Introduction
High-doseionizingradiationcausesdamagetomanyorgans,
especially those with highly proliferative cells such as the
bone marrow and the gastrointestinal tract [1, 2]. Bone mar-
row failure is often the cause of death following moderate-
to-severe exposures to radiation [3]. Several pharmacologic
agents especially cytokines such as granulocyte colony stim-
ulating factor (GCSF), granulocyte monocyte colony stim-
ulating factor (GMCSF), interleukin 3 (IL3), and throm-
bopoietin (TPO) have been shown in various experimental
models to mitigate hematopoietic eﬀects of radiation and are
approved for clinical use in scenarios of radiation-induced
aplasia [4–6]. The eﬃcacy of these agents is, however, limited
to intermediate dose ranges which do not result in complete
marrow ablation. Exposure to higher doses that result
in complete marrow ablation requires the transplantation
of a new lympho-hematopoietic system from a suitable
donor [7]. As such transplantations are impractical to be
performed expeditiously following exposure to high-dose
radiation (accidental or nuclear attacks), there is signiﬁcant
interest in improving the eﬃcacy of pharmacological agents
as mentioned above and explore novel agents with eﬃcacy
at doses higher than what cytokines are typically eﬀective.
“Oﬀ-the shelf” cellular therapies that can be expanded from
a few initial cells, frozen, and thawed for quick infusion and
do not require extensive tissue-matching have been explored
as alternatives to full allogeneic stem cell transplantation
following such radiation exposures. Marrow stromal cells
(MSCs,alsoreferredtoasmesenchymalstemcells)havebeen
proposed as one such cellular therapy to aid regeneration
of radiation-induced aplasia; MSCs have shown promise
in preclinical studies in rodents and uncontrolled human
trials to aid in the regeneration of damaged tissues in
experimental models simulating acute graft versus graft
disease (aGVHD) [8], renal failure [9], diabetes mellitus
[10], and myocardial infarction [11]. However, despite
enormous interest in using MSCs to aid in hematopoietic
regeneration following radiation exposure, the beneﬁt of
MSC infusion on survival after radiation induced marrow
damage has only been addressed by a few recent studies
[12, 13]. In this study, we sought to determine if a single
dose of MSC (either cloned or primary MSC cultures)
following lethal dose irradiation would improve survival
in the murine model. We also determined the spatial and
temporal distribution of infused MSCs in recipients to help2 Advances in Hematology
better understand the mechanism of action of these cells in
improving hematopoietic reconstitution.
2. Methods
2.1. Marrow Stromal Cells. Murine MSC lines were isolated
by transducing a primary long-term culture of murine
bone marrow with the LXSN-16 E6E7 retrovirus (encoding
human papilloma viruses E6 and E7) followed by selection
in G418 and ring-cloning as previously described [14]. Five
MSC lines (denoted B6M1, 6, 7, 9, and 11) were used for
further studies mixed in equal ratio. Primary MSCs were
prepared by plating whole marrow mononuclear cells from
adult female mice in DMEM supplemented with 10% fetal
bovine serum, cultured till conﬂuence, and expanded 3-4
passages. Both the cloned and primary MSCs were analyzed
for ability to diﬀerentiate to osteoblastic, chondroblastic
by utilizing commercial kits (Invitrogen, Carlsbad, CA)
and adipocytic lineage by previously described techniques
[15] (Supplementary Methods and Supplementary Figure 1
available online at doi:10.1155/2012/142530).
2.2. Animals and MSC Infusion. All animal studies were
approved by the University of Colorado Denver’s animal care
and use committee (IACUC). Female C57/Bl6 mice (Jack-
son Laboratories, Bar Harbor, ME) 6 to 8 weeks of age
were used as recipients of MSC infusion. MSCs were sus-
pended in 100μL of PBS (phosphate buﬀered saline) for
infusion. Radiation was delivered using an X-ray irradiator
(RS2000, Rad Source Technologies, Suwanee, GA) in two
splitdoses.Drinkingwaterwassupplementedwithneomycin
(150mg/L) and bacitracin (5mg/L) to minimize infections
[16]. Single MSC infusion was performed by tail vein
injection from 16 to 24 hours after radiation. All animals
were monitored for at least 7 weeks to document survival
from radiation. Animals were monitored closely for evidence
of distress resulting from hematopoietic failure (weight loss
of over 15% of baseline, signs of infection, decreased feeding
or activity) and were euthanized if deemed in irreversible
distress.
2.3. Bioluminescent Imaging (BLI or In Vivo Imaging) of
Labeled MSCs. BLI was performed using Xenogen IVIS 200
system, MSCs labeled with ﬁre ﬂy luciferin (ﬄuc) were
infused as described above and imaged at 4, 7, 24, and 72
hours after MSC infusion by intraperitoneal injection of
luciferin and visualization as previously described [16]a n d
detailed in Supplementary Methods.
2.4. Immune Histochemistry (IHC) and Quantitative Real-
Time PCR (qRT PCR) for Fireﬂy Luciferase (Fﬂuc). IHC was
performed with mouse anti-ﬄuc antibody or isotype control
(Novus biological) per published protocols on formalin-
ﬁxed paraﬃn embedded tissues harvested at days 4 or 7 after
infusionoflabeledMSCs[17].TotalRNAwasextractedfrom
tissues at same time points and quantitative real-time PCR
was performed on cDNA prepared from RNA with primers
speciﬁc to ﬄuc or housekeeping gene TBP (Supplementary
Methods).
2.5. Statistical Analyses. Kaplan Meir survival curves were
constructed and P values calculated using MedCalc Software
(Mariakerke, Belgium).
3. Results and Discussion
3.1. Single Infusion of MSCs Signiﬁcantly Improves Survival
in Lethally Irradiated Mice. Both the cloned MSC cell lines
and primary MSCs were characterized for their ability to dif-
ferentiate to adipogenic, chondrogenic, and osteogenic lin-
eage by appropriate diﬀerentiation assays (Supplementary
Figure 1). To assess the survival beneﬁt of MSC infusion
after hematopoietic injury from ionizing radiation, we ﬁrst
determined a suitable dose of radiation, which is lethal to
mostoftherecipientswhenanX-rayirradiator(RS2000)was
used.Byadministeringincreasingdosesofradiation(starting
at 600cGy and increasing in increments of 100cGy), it
was determined that there was almost universal fatality
at doses 700cGy and higher when no speciﬁc therapeutic
intervention was performed other than supportive care.
Hence studies to determine eﬃcacy of MSC infusion were
performed at 700cGy dose (Figure 1(a)). Mice that received
700cGy of radiation were then treated with one of the
following interventions: (1) single infusion of clonal MSC
cells (mixture of 5 MSC cell lines in equal ratio, hence forth
referred to as cMSC at total dose of 1 × 106 cells, n = 19) (2)
primary MSC (p MSC, at a dose of 1 × 106 cells, n = 20),
or (3) 100μL of PBS (n = 21). As shown in Figure 1(b),
animals receiving either cMSC or pMSC had signiﬁcantly
improved survival when compared to the control PBS only
group(P = 0.017 and 0.041, resp.) at the end of 7 weeks after
radiation and cell infusion.
3.2. MSCs Are Rapidly Cleared after Infusion. Although
MSCs have shown promise to aid tissue repair in several
clinical scenarios of tissue injury, the mechanistic basis of
this beneﬁcial eﬀect remains unclear. Whole-organism
imaging modalities including radio-isotype labeling [18–
20], magnetic resonance imaging (MRI) [21, 22], and in
vivo bioluminescence imaging (BLI) [23–25]h a v eb e e n
used to determine the spatial and temporal distribution
patterns of infused MSCs in diﬀerent organs. These studies
have generally shown that most of the infused cells are
trapped in the lungs after systemic intravenous infusion
and a small proportion is detectable in the target organs at
various later time points. We hence attempted to determine
the spatial distribution and kinetics of cMSC after infusion
by three separate techniques. The ﬁve MSC cell lines were
engineered to stably express ﬁreﬂy luciferase (ﬄuc) by use of
lentiviralvectors.Wethenusedbioluminescentimagingafter
intraperitoneal injection of luciferin substrate to determine
tissue distribution of MSCs at speciﬁc time points after
infusion. As shown in Figure 2(a), strong bioluminescent
signals were detected from the chest region starting at
4 hours after infusion. The BLI signals rapidly decreased
during the ﬁrst 24 hours, and no bioluminescent signal was
detected at 3 days after infusion. BLI signals were also not
detected in any organ outside the thorax at any time point.
Given that at least a few thousand cells expressing ﬄucAdvances in Hematology 3
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Figure 1: Impact of MSC infusion on survival of C57/Bl6 mice. (a) Determination of lethal dose of radiation for C57/Bl6 mice when
radiation delivered with the RS2000 X-ray irradiator. Adult female mice 6 to 8 weeks in age were radiated with 600, 700, or 800cGy radiation
(n = 5 each) in two divided doses survival rate calculated at 7 weeks after radiation. None of the animals that received 700 or 800cGy
radiation survived past 4 weeks from day of radiation. 4 of the 5 mice in the 600cGy radiation group survived past 7 weeks from day of
radiation (P<0.001). (b) Survival of mice receiving MSCs (clones or primary) when compared to control animals. Survival was studied in
adult female mice receiving 700cGy radiation followed by one of the following interventions: cloned MSCs (cMSC, n = 19), primary MSCs
(pMSC, n = 20) or PBS (n = 21). Survival was signiﬁcantly better for the cMSC (53%) and pMSC (60%) groups when compared to PBS (P
values of 0.017 and 0.041, resp. with logrank test) at 7 weeks after radiation.
are necessary for unequivocal photon signals for BLI, we
then attempted to determine the presence of ﬄuc expressing
cells by both immune histochemistry (IHC) and polymerase
chain reactions. Fﬂuc could not be reliably detected in
any tissues including lungs by IHC at any time point
presumably again due to their distribution across the entire
pulmonary vasculature and not as discrete clumps of cells.
Using reverse transcription and quantitative PCR, we then
analyzed RNA from multiple tissues at three time points
after infusion (days 1, 4, and 7) for presence of ﬄuc
mRNA. As shown in Figure 2(b), ﬄuc was detectable in
all animals one day after MSC infusion in the lungs, but
mostly undetectable in any other tissue. On days 4 and 7,
mRNA were detectable in other tissues also. Interestingly,
cardiac and gut tissues showed a progressive increase in
the proportion of animals with detectable ﬄuc transcript.
Detection of transcripts using highly sensitive RT-PCR in
the absence of BLI or IHC positivity suggests that the
signals might arise from unviable cells or cellular debris
that redistributed from the lung or from circulating RNA in
peripheral blood. Together, these results suggest that most
MSCsarepassivelyﬁlteredbythelungandfewviablecellsare
redistributed from the lungs to other tissues after systemic
infusion.
In summary, our results show that a single infusion of
syngeneic marrow stromal cells (either immortalized cell
lines or primary cells) can signiﬁcantly improve hematopoi-
etic recovery after lethal ionizing radiation in the murine
model. These results are in agreement with another recent
report from Lange et al. which also reported improved
survival of lethally irradiated mice when MSCs are infused
[12].Althoughconcomitantdetermination ofhematopoietic
recovery by sampling of peripheral blood at diﬀerent time
points after radiation and MSC infusion would have added
further signiﬁcance to these results, our pilot experiments
revealed high mortality from repeated blood sampling in
these animals (data not shown) and hence this experi-
mental methodology was abandoned. Given that survival
from similar dose range of ionizing radiation has been
well documented to depend on hematopoietic recovery [1,
2]; survival alone was felt to be a robust and suﬃcient
end point to study. Results from our study extend these
observations by Lange et al. [12] to show that the infused
cells are cleared rapidly by ﬁltration in the lungs with
little redistribution to other tissues including bone marrow.
Consequently, the beneﬁt of MSC infusion is likely to be
indirect, mediated through release of soluble factors either
from the MSC themselves or through other cells such as
monocytes/macrophages, which interact with the MSCs in
the lung. Although MSC infusion is clearly beneﬁcial follow-
ingionizingradiation,themechanisticbasisofMSC-induced
regeneration in various tissues including hematopoietic tis-
sues remains unknown. Understanding the biological path-
w a y sw o u l dh e l pt of u r t h e ri m p r o v ee ﬃcacy of MSC-based
therapeutics.4 Advances in Hematology
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Figure 2: Tissue distribution of MSCs in vivo after injection. A. Bioluminescent imaging (BLI) of MSCs at 4, 7, and 24 hours after injection.
1 × 106 MSC cells stably expressing ﬄuc were infused into recipient mice by tail vein injection followed by Bioluminescent signals were
restricted to the thoracic area. Signals decreased rapidly and were undetectable 72 hours after infusion. B. Quantitative RT-PCR for ﬄuc in
the above tissues harvested at 1, 4, and 7 days after infusion (n = 6 each). Whole RNA was prepared from tissues and analyzed for presence
of ﬄuc mRNA by q RT-PCR. Since ﬄuc expression cannot be normalized to any endogenous control, equal quantities of starting material
(2μg of whole RNA) were used for cDNA synthesis. Those samples with mean Ct < 35 cycles were deemed as positive for ﬄuc expression.
All animals had detectable levels of ﬄuc mRNA in their lungs on day 1, while most other tissues had no detectable transcript on day 1. On
days 4 and 7, there were detectable levels of ﬄuc transcripts detectable in a variable proportion of all tissues from some animals.
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